Since the NAMPT inhibitor FK866 suffers from a number of serious side effects, including thrombocytopenia, lymphopenia and anemia, as well as severe nausea and mild fatigue [16], we sought to identify other potentially less toxic metabolic approaches for targeting CSCs. The gene discussed is NAMPT; the disease is anemia.